Seguridad
Adverse reaction profile in LITESPARK-005 (N=327 patients)
aAnemia includes anemia and haemoglobin decreased.
- In LITESPARK-005, the median duration of exposure to WELIREG was 7.6 months (range: 0.1–35.8 months).
- The most common adverse reactions under treatment with WELIREG were anemia (83%), fatigue (31%), dyspnea (15%), hypoxia (15%), nausea (18%), and dizziness (12%).
- The most common adverse reactions resulting in dose interruption of WELIREG were anemia (8.6%), hypoxia (5.6%), fatigue (1.6%), dizziness (1.6%), dyspnea (1.6%), and nausea (1.3%).
- The most common adverse reactions resulting in dose reduction of WELIREG were hypoxia (5.6%) and anemia (3.0%).
- WELIREG was discontinued due to adverse reaction in 5.9% of patients.
Anti–PD-1/L1 = anti–PD-1 or anti–PD-L1; PD-1 = programmed death receptor-1; PD-L1 = programmed death ligand 1; VEGF-TKI = vascular endothelial growth factor tyrosine kinase inhibitor; RCC = renal cell carcinoma.
[Indication Placeholder]
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
[SSI Placeholder]
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.